There are currently no anti-NG2 therapies approved for the use in humans, but there is a clinical trial (NCT06096038) underway to test the safety and efficacy of T cells expressing CSPG4-specific Chimeric Antigen Receptors (CAR) in persons with head and neck squamous cell carcinoma. The gene discussed is CSPG4; the disease is head and neck squamous cell carcinoma.